Table 2. Follow-up data and clinical outcomes of patients with IgA nephropathy.
| Follow up data | n = 130 (%) | Mean ± (SD) or Median (IQR) |
|---|---|---|
| Duration of follow up; median (years) | 7.5 (4.0 to 13.0) | |
| TA Proteinuria (g/day) | 0.7 (0.4 to 1.4) | |
| TA Proteinuria (%) | ||
| <0.5 | 36 (27.7) | |
| ≥0.5 <1.0 | 42 (32.3) | |
| ≥1.0 <1.5 | 20 (15.4) | |
| ≥1.5 <2.0 | 13 (10) | |
| ≥ 2.0 <2.5 | 7 (5.4) | |
| ≥ 2.5 <3.0 | 5 (3.8) | |
| ≥ 3.0 | 7 (5.4) | |
| Immunosuppression◊ | ||
| Corticosteroid (%) | 83 (63.8) | |
| Cyclophosphamide (%) | 35 (26.9) | |
| MMF (%) | 16 (12.3) | |
| Calcineurin inhibitors (%) | 33 (25.4) | |
| Azathioprine (%) | 17 (13.1) | |
| Non-immunosuppression◊ | ||
| RAAS Blockade (%) | 122 (93.8) | |
| Fish Oil (%) | 82 (63.1) | |
| Calcium Channel Blocker (%) | 73 (56.2) | |
| Antiplatelet agents (%) | 13 (10) | |
| Long term Complication◊(%) | ||
| Diabetes Mellitus | 20 (15.4) | |
| Malignancy | 5 (3.8) | |
| Renal Biopsy Oxford MEST-C Scoring | ||
| M1 | 65 (50) | |
| E1 | 13 (10) | |
| S1 | 88 (67.7) | |
| T1 | 22 (16.9) | |
| T2 | 11 (8.5) | |
| C1 | 27 (20.8) | |
| C2 | 7 (5.4) | |
| Clinical Outcome Data | ||
| Rate of decline in renal function (ml/min/1.73m2/year) | - 2.1 (-5.3 to -0.1) | |
| ESRD (<15ml/min/1.73m2) | 18 (13.8) | |
| 50% decrease in eGFR | 33 (25.4) | |
| 50% decrease in eGFR or ESRD | 34 (26.2) | |
TA: time average, MMF: Mycophenolate Mofetil, RAAS: renin-angiotensin-aldosterone system, eGFR: estimated glomerular filtration rate, ESRD: End Stage Renal Disease.
◊Each patient can have more than one treatment group and long-term complications. Results are expressed as mean ± SD, median (interquartile range), or percentage.